Independent patterns of damage within magno-, parvo- and koniocellular pathways in Parkinson's disease

Brain

Volumn 128, Issue 10, 2005, Pages 2260-2271

  Silva, M F ^a   Faria, P ^a   Regateiro, F S ^a   Forjaz, V ^a   Januario C ^a   Freire, A ^a   Castelo Branco, M ^a  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

Contrast sensitivity; Koniocellular; Magnocellular; Parkinson's disease; Parvocellular

Indexed keywords

AGING; ARTICLE; BRAIN INJURY; CELL FUNCTION; COLOR VISION; CONTRAST SENSITIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; GIANT CELL; HUMAN; INTRAOCULAR PRESSURE; LUMINANCE; MEASUREMENT; NEUROOPHTHALMOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; RETINOPATHY; STIMULUS RESPONSE; VISUAL IMPAIRMENT; VISUAL SYSTEM;

EID: 26044475845     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awh581     Document Type: Article

References (80)

1. Bach M. Electrophysiological approaches for early detection of glaucoma. Eur J Ophthalmol 2001; 11 (Suppl 2): S41-9.
2. Birch J, Kolle RU, Kunkel M, Paulus W, Upadhyay P. Acquired colour deficiency in patients with Parkinson's disease. Vision Res 1998; 38: 3421-6.
3. Bodis-Wollner I. Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients. Trends Neurosci 1990; 13: 296-302.
4. Bodis-Wollner I. Neuropsychological and perceptual defects in Parkinson's disease. Parkinsonism Relat Disord 2003; 9: 83-9.
5. Bodis-Wollner I, Regan D. Spatiotemporal contrast vision in Parkinson's disease and MPTP-treated monkeys: the role of dopamine. pp. 250-60.
6. Bodis-Wollner I, Tzelepi A. The push-pull action of dopamine on spatial tuning of the monkey retina: the effects of dopaminergic deficiency and selective D1 and D2 receptor ligands on the pattern electroretinogram. Vision Res 1998; 38: 1479-87.
7. Bodis-Wollner I, Yahr MD. Measurements of visual evoked potentials in Parkinson's disease. Brain 1978; 101: 661-71.
8. Bodis-Wollner I, Marx MS, Mitra S, Bobak P, Mylin L, Yahr M. Visual dysfunction in Parkinson's disease. Loss in spatiotemporal contrast sensitivity. Brain 1987; 110: 1675-98.
9. Bohnen NI, Minoshima S, Giordani B, Frey KA, Kuhl DE. Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia. Neurology 1999; 52: 541-6.
10. Bulens C, Meerwaldt JD, Van der Wildt GJ. Effect of stimulus orientation on contrast sensitivity in Parkinson's disease. Neurology 1988; 38: 76-81.
11. Buttner T, Kuhn W, Patzold T, et al. L-dopa improves colour vision in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1994; 7: 13-9.
12. Buttner T, Kuhn W, Muller T, Patzold T, Heidbrink K, Przuntek H. Distorted color discrimination in 'de novo' Parkinsonian patients. Neurology 1995; 45: 386-7.
13. Buttner T, Muller T, Kuhn W. Effects of apomorphine on visual functions in Parkinson's disease. J Neural Transm 2000; 107: 87-94.
14. Campos SH, Forjaz V, Kozak LR, Silva E, Castelo-Branco M. Quantitative phenotyping of chromatic dysfunction in Best macular dystrophy. Arch Ophthalmol 2005; 123: 944-9.
15. Castelo-Branco M, Faria P, Forjaz V, Kozak LR, Azevedo H. Simultaneous comparison of relative damage to chromatic pathways in ocular hypertension and glaucoma: correlation with clinical measures. Invest Ophthalmol Vis Sci 2004; 45: 499-505.
16. Cello KE, Nelson-Quigg JM, Johnson CA. Frequency doubling technology perimetry for detection of glaucomatous visual field loss. Am J Ophthalmol 2000; 129: 314-22.
17. Crucian GP, Okun MS. Visual-spatial ability in Parkinson's disease. Front Biosci 2003; 8: 992-7.
18. Curcio CA, Sloan KR, Kalina RE, Hendrickson AE. Human photoreceptor topography. J Comp Neurol 1990; 292: 497-523.
19. Delalande L, Destee A, Hache JC, Forzy G, Bughin M, Benhadjali J. Visual evoked potentials and spatiotemporal contrast sensitivity changes in idiopathic Parkinson's disease and multiple system atrophy. Adv Neurol 1996; 69: 319-25.
20. Derrington AM, Lennie P. Spatial and temporal contrast sensitivities of neurons in lateral geniculate nucleus of macaque. J Physiol 1984; 357: 219-40.
21. Diederich NJ, Raman R, Leurgans S, Goetz CG. Progressive worsening of spatial and chromatic processing deficits in Parkinson's disease. Arch Neurol 2002; 59: 1249-52.
22. Fiorentini A, Maffei L, Pirchio M, Spinelli D, Porciatti V. The ERG in response to alternating gratings in patients with diseases of the peripheral visual pathway. Invest Ophthalmol Vis Sci 1981; 21: 490-3.
23. Folstein MF, Folstein, SE, Mchugh, PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12: 189-98.
24. Geldmacher DS. Visuospatial dysfunction in the neurodegenerative diseases. Front Biosci 2003; 8: 428-36.
25. Glovinsky Y, Quigley HA, Pease ME. Foveal ganglion cell loss is size dependent in experimental glaucoma. Invest Ophthalmol Vis Sci 1993; 34: 395-400.
26. Guerreiro M, Silva AP, Botelho MA. Adaptação à população portuguesa na tradução do "Mini Mental State Examination" (MMSE). Rev Port de Neurol 1994; 1: 9.
27. Han Y, Adams AJ, Bearse MA Jr, Schneck ME. Multifocal electroretinogram and short-wavelength automated perimetry measures in diabetic eyes with little or no retinopathy. Arch Ophthalmol 2004; 122: 1809-15.
28. Harnois C, di Paolo T. Decreased dopamine in the retinas of patients with Parkinson's disease. Invest Ophthalmol Vis Sci 1990; 31: 2473-5.
29. Harris JP. Vision in Parkinson's disease: what are the deficits and what are their origins? Neuroophthalmology 1998; 19: 113-35.
30. Harris JP, Calvert JE, Phillipson OT. Processing of spatial contrast in peripheral vision in Parkinson's disease. Brain 1992; 115: 1447-57.
31. Harrison JM, O'Connor PS, Young RS, Kincaid M, Bentley R. The pattern ERG in man following surgical resection of the optic nerve. Invest Ophthalmol Vis Sci 1987; 28: 492-9.
32. Haug BA, Trenkwalder C, Arden GB, Oertel WH, Paulus W. Visual thresholds to low-contrast pattern displacement, color contrast, and luminance contrast stimuli in Parkinson's disease. Mov Disord 1994; 9: 563-70.
33. Haug BA, Kolle RU, Trenkwalder C, Oertel WH, Paulus W. Predominant affection of the blue cone pathway in Parkinson's disease. Brain 1995; 118: 771-8.
34. Ikeda H, Head GM, Ellis CJ. Electrophysiological signs of retinal dopamine deficiency in recently diagnosed Parkinson's disease and a follow up study. Vision Res 1994; 34: 2629-38.
35. Inzelberg R, Ramirez JA, Nisipeanu P, Ophir A. Retinal nerve fiber layer thinning in Parkinson disease. Vision Res 2004; 44: 2793-7.
36. Jackson GR, Owsley C. Visual dysfunction, neurodegenerative diseases, and aging. Neurol Clin 2003; 21: 709-28.
37. Johnson CA, Samuels SJ. Screening for glaucomatous visual field loss with frequency-doubling perimetry. Invest Ophthalmol Vis Sci 1997; 38: 413-25.
38. Kaplan E, Shapley RM. X and y cells in the lateral geniculate nucleus of macaque monkeys. J Physiol 1982; 330: 125-43.
39. Kelly DH. Nonlinear visual responses to flickering sinusoidal gratings. J Opt Soc Am 1981; 71: 1051-5.
40. Landers J, Goldberg I, Graham S. A comparison of short wavelength automated perimetry with frequency doubling perimetry for the early detection of visual field loss in ocular hypertension. Clin Exp Ophthalmol 2000; 28: 248-52.
41. Langheinrich T, Tebartz van Elst L, LaGreze W, Bach M, Lücking CH, Greenlee MW. Visual contrast response functions in Parkinson's disease: evidence from PERG, VEP and psychophysics. Clin Neurophysiol 2000; 111: 66-74.
42. Lee BB. Receptive field structure in the primate retina. Vision Res 1996; 36: 631-44.
43. Lynch JJ III, Silveira LC, Perry VH, Merigan WH. Visual effects of damage to P ganglion cells in macaques. Vis Neurosci 1992; 8: 575-83.
44. Maddess T, Henry GH. Nonlinear visual responses and visual deficits in ocular hypertensive and glaucoma subjects. Clin Vis Sci 1992; 7: 371-83.
45. Maddess T, Goldberg I, Wine S, Dobinson J, Welsh AH, James AC. Testing for glaucoma with the spatial frequency doubling illusion. Vision Res 1999; 39: 4258-73.
46. Marx M, Bodis-Wollner I, Bobak P, Harnois C, Mylin L, Yahr M. Temporal frequency-dependent VEP changes in Parkinson's disease. Vision Res 1986; 26: 185-93.
47. McKendrick AM, Anderson AJ, Johnson CA, Fortune B. Appearance of the frequency doubling stimulus in normal subjects and patients with glaucoma. Invest Ophthalmol Vis Sci 2003; 44: 1111-16.
48. Merigan WH, Maunsell JHR. How parallel are the primate visual pathways? Annu Rev Neurosci 1993; 16: 369-402.
49. Mestre D, Blin O, Serratrice G, Pailhous J. Human spatio-temporal contrast sensitivity: dopaminergic induced variations. Eur J Pharmacol 1990a; 183: 1022-3.
50. Mestre D, Blin O, Serratrice G, Pailhous J. Spatiotemporal contrast sensitivity differs in normal aging and Parkinson's disease. Neurology 1990b; 40: 1710-4.
51. Mestre D, Blin O, van den Brand CL, Azulay JP, Serratrice G. Effects of L-dopa on spatiotemporal contrast sensitivity in Parkinson's disease. Adv Neurol 1996; 69: 503-11.
52. Nguyen-Legros J. Functional neuroarchitecture of the retina: hypothesis on the dysfunction of retinal dopaminergic circuitry in Parkinson's disease. Surg Radiol Anat 1988; 10: 137-44.
53. Packer O, Williams DR. Light, the retinal image, and photoreceptors. In: Shevell SK, editor. The science of color. 2nd ed., Chapter 2. Oxford: Elsevier; 2003.
54. Paczka JA, Friedman DS, Quigley HA, Barron Y, Vitale S. Diagnostic capabilities of frequency-doubling technology, scanning laser polarimetry, and nerve fibre layer photographs to distinguish glaucomatous damage. Am J Ophthalmol 2001; 131: 188-97.
55. Pearson P, Swanson WH, Fellman RL. Chromatic and achromatic defects in patients with progressing glaucoma. Vision Res 2001; 41: 1215-27.
56. Pieri V, Diederich NJ, Raman R, Goetz CG. Decreased color discrimination and contrast sensitivity in Parkinson's disease. J Neurol Sci 2000; 172: 7-11.
57. Pokorny J, Smith VC, Lutze M. Aging of the human lens. Appl Opt 1987; 26: 1437-40.
58. Price MJ, Feldman RG, Adelberg D, Kayne H. Abnormalities in color vision and contrast sensitivity in Parkinson's disease. Neurology 1992; 42: 887-90.
59. Purpura K, Kaplan E, Shapley RM. Background light and the contrast gain of primate P and M retinal ganglion cells. Proc Natl Acad Sci USA 1988; 85: 4534-37.
60. Purpura K, Trachina D, Kaplan E, Shapley RM. Light adaptation in the primate retina: analysis of changes in the gain and dynamics of monkey retinal ganglion cells. Vis Neurosci 1990; 4: 75-93.
61. Quigley HA, Sanchez RM, Dunkelburger GR, Henaut NL, Baginski TA. Chronic glaucoma selectively damages large optic nerve fibers. Invest Ophthalmol Vis Sci 1987; 28: 913-8.
62. Quigley HA, Dunkelberger GR, Green WR. Chronic human glaucoma causing selectively greater loss of large optic nerve fibers. Ophthalmology 1988; 95: 357-63.
63. Reeves BC, Hill AR, Aspinall PA. Normative data for the significance of change in error score of the Farnsworth Munsell 100 hue test. Doc Ophthalmol Proc Ser 1989; 52: 417-23.
64. Regan D, Maxner C. Orientation-selective visual loss in patients with Parkinson's disease. Brain 1987; 110: 415-32.
65. Regan BC, Reffin JP, Mollon JD. Luminance noise and the rapid determination of discrimination ellipses in colour deficiency. Vision Res 1994; 34: 1279-99.
66. Regan BC, Freudenthaler N, Kolle R, Mollon JD, Paulus W. Colour discrimination thresholds in Parkinson's disease: results obtained with a rapid computer-controlled colour vision test. Vision Res 1998; 38: 3427-31.
67. Roth A, Lanthony P. Vision des couleurs. In: Risse JF, editor. Exploration de la fonction visuelle. Paris: Masson; 1999. p. 129-51.
68. Shabana N, Peres VC, Carkeet A, Chew PT. Motion perception in glaucoma patients. Surv Ophthalmol 2003; 48: 92-106.
69. Shapley RM, Victor JD. The effect of contrast on the non-linear response of the Y-cell. J Physiol 1980; 302: 535-47.
70. Shevell SK. The science of color. 2nd ed. Oxford: Elsevier; 2003.
71. Siegel S, Castellan NJ. Nonparametric statistics for the behavioural sciences. New York: McGraw-Hill; 1988.
72. Silva MF, Guerreiro M, Castelo-Branco M. Disadvantage of the superotemporal field in normal subjects as revealed by techniques that study the function of the magnocellular pathway. Ophthalmic Res 2004; 36: S1-60.
73. Silveira LC, Perry VH. The topography of magnocellular projecting ganglion cells (M-ganglion cells) in the primate retina. Neuroscience 1991; 40: 217-37.
74. Skrandies W, Gottlob I. Alterations of visual contrast sensitivity in Parkinson's disease. Hum Neurobiol 1986; 5: 255-9.
75. Tagliati M, Bodis-Wollner I, Yahr MD. The pattern electroretinogram in Parkinson's disease reveals lack of retinal spatial tuning. Electroencephalogr Clin Neurophysiol 1996; 100: 1-11.
76. Tebartz van Elst L, Greenlee MW, Foley JM, Lucking CH. Contrast detection, discrimination and adaptation in patients with Parkinson's disease and multiple system atrophy. Brain 1997; 120: 2219-28.
77. Trible JR, Schultz RO, Robinson JC, Rothe TL. Accuracy of glaucoma detection with frequency-doubling perimetry. Am J Ophthalmol 2000; 129: 740-45.
78. Werner JS, Peterzell DH, Scheetz AJ. Light, vision, and aging. Optom Vis Sci 1990; 67: 214-29.
79. Wyszecki G, Stiles WS. Color science: concepts and methods, quantitative data and formulae. 2nd ed., Chapter 5. New York: John Wiley; 1982. p. 353-4.
80. Yamada ES, Silveira LC, Perry VH, Franco EC. M and P retinal ganglion cells of the owl monkey: morphology, size and photoreceptor convergence. Vision Res 2001; 41: 119-31.